← Human Trials & Peer-Reviewed Studies
Perioperative growth hormone treatment and functional outcome after major abdominal surgery: a randomized, double-blind, controlled study.
Plain-language guide to PMID 10024114 (1999): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 10024114
- Journal
- Annals of surgery
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Kissmeyer-Nielsen P et al. (3 authors)
- DOI
- 10.1097/00000658-199902000-00020
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To evaluate short- and long-term effects of perioperative human growth hormone (hGH) treatment on physical performance and fatigue in younger patients undergoing a major abdominal operation in a normal postoperative regimen with oral nutrition.
Why It Was Studied
Muscle wasting and functional impairment follow major abdominal surgery.
Who Took Part
By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, both men and women.
Measurements were performed 2 days before and 10, 30, and 90 days after surgery.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Colitis, Ulcerative, Fatigue, Heart Rate, Human Growth Hormone, Muscle, Skeletal, Postoperative Care and Postoperative Complications.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1999 (Annals of surgery), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.